- Home
- KYMR vs ARE Comparison
KYMR vs ARE Comparison
Compare KYMR & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYMR | ARE |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.3B |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | KYMR | ARE |
|---|---|---|
| Price | $110.28 | $50.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 26 | 11 |
| Target Price | ★ $107.72 | $56.22 |
| AVG Volume (30 Days) | 682.9K | ★ 1.4M |
| Earning Date | 04-30-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 11.40% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.10 |
| Revenue | $39,211,000.00 | ★ $3,026,556,000.00 |
| Revenue This Year | $10.61 | N/A |
| Revenue Next Year | $8.17 | $0.15 |
| P/E Ratio | ★ N/A | $24.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $36.88 | $39.41 |
| 52 Week High | $130.05 | $88.24 |
Technical Indicators
Market Signals| Indicator | KYMR | ARE |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 52.92 |
| Support Level | $108.87 | $50.10 |
| Resistance Level | $120.90 | $55.27 |
| Average True Range (ATR) | 5.47 | 1.46 |
| MACD | -1.68 | 0.08 |
| Stochastic Oscillator | 22.52 | 83.99 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
About ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.